Cetuximab, which inhibits EGFR, plus encorafenib, a small molecule BRAF inhibitor, could also improve the progression-free survival (PFS) for CRC patients with a BRAF V600E mutation (Tabernero et al., 2021). Here, EGFR is linked to colorectal carcinoma.